Table 2.
Incidence rate ratio (IRR) of adenosquamous cell carcinoma and rare types of invasive cervical carcinoma by screening status in previous two screening intervals in women aged over 30
| Screening status | Adenosquamous cell carcinoma (n=155) | Rare types of invasive cervical carcinoma* (n=152) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Cases—No (%) | Controls—No (%) | Crude IRR (95% CI) | Adjusted† IRR (95% CI) | Cases—No (%) | Controls—No (%) | Crude IRR (95% CI) | Adjusted† IRR (95% CI) | ||
| Cases aged ≥30 years | |||||||||
| No test | 65 (42) | 954 (21.5) | Reference | Reference | 70 (46) | 1461 (33.8) | Reference | Reference | |
| One test | 44 (28) | 1290 (29.0) | 0.40 (0.26 to 0.60) | 0.39 (0.26 to 0.59) | 47 (31) | 1169 (27.1) | 0.64 (0.42 to 0.99) | 0.69 (0.45 to 1.06) | |
| Two tests | 46 (30) | 2197 (49.5) | 0.22 (0.15 to 0.34) | 0.22 (0.14 to 0.34) | 35 (23) | 1691 (39.1) | 0.31 (0.19 to 0.49) | 0.34 (0.21 to 0.55) | |
| Age at diagnosis | |||||||||
| 30-60 years: | |||||||||
| No test | 35 (33) | 367 (12.0) | Reference | Reference | 23 (32) | 281 (13.3) | Reference | Reference | |
| One test | 33 (31) | 904 (29.5) | 0.38 (0.23 to 0.63) | 0.38 (0.23 to 0.62) | 28 (39) | 633 (29.9) | 0.54 (0.30 to 0.95) | 0.52 (0.29 to 0.94) | |
| Two tests | 37 (35) | 1789 (58.5) | 0.21 (0.13 to 0.34) | 0.21 (0.13 to 0.34) | 22 (30) | 1200 (56.8) | 0.22 (0.12 to 0.40) | 0.22 (0.12 to 0.40) | |
| >60 years: | |||||||||
| No test | 30 (60) | 587 (42.5) | Reference | Reference | 47 (59) | 1180 (53.5) | Reference | Reference | |
| One test | 11 (22) | 386 (28.0) | 0.43 (0.20 to 0.92) | 0.42 (0.19 to 0.90) | 19 (24) | 536 (24.3) | 0.76 (0.41 to 1.42) | 0.82 (0.44 to 1.54) | |
| Two tests | 9 (18) | 408 (29.5) | 0.29 (0.12 to 0.69) | 0.28 (0.11 to 0.67) | 13 (16) | 491 (22.2) | 0.53 (0.26 to 1.11) | 0.61 (0.29 to 1.27) | |
| FIGO stage ‡ | |||||||||
| IA: | |||||||||
| No test | 2 (20) | 87 (30) | Reference | Reference | 1 (20) | 48 (34) | Reference | Reference | |
| One test | 5 (50) | 82 (28) | 3.49 (0.44 to 27.52) | 3.00 (0.37 to 24.31) | 4 (80) | 47 (33) | 3.75 (0.39 to 36.30) | 3.46 (0.35 to 33.94) | |
| Two tests | 3 (30) | 122 (42) | 1.42 (0.14 to 14.25) | 1.10 (0.10 to 11.81) | 0 (0) | 48 (34) | - | - | |
| IB: | |||||||||
| No test | 34 (37.0) | 453 (17.0) | Reference | Reference | 19 (33) | 415 (25.4) | Reference | Reference | |
| One test | 27 (29.3) | 797 (30.0) | 0.40 (0.23 to 0.68) | 0.38 (0.22 to 0.66) | 23 (40) | 457 (28.0) | 0.98 (0.49 to 1.95) | 0.92 (0.46 to 1.86) | |
| Two tests | 31 (33.7) | 1411 (53.0) | 0.24 (0.14 to 0.41) | 0.23 (0.13 to 0.39) | 15 (26) | 762 (46.6) | 0.36 (0.17 to 0.77) | 0.34 (0.16 to 0.75) | |
| II+: | |||||||||
| No test | 29 (55) | 414 (27.8) | Reference | Reference | 50 (56) | 998 (39.2) | Reference | Reference | |
| One test | 12 (23) | 411 (27.6) | 0.29 (0.14 to 0.60) | 0.29 (0.14 to 0.60) | 20 (22) | 665 (26.1) | 0.40 (0.22 to 0.74) | 0.44 (0.24 to 0.81) | |
| Two tests | 12 (23) | 664 (44.6) | 0.15 (0.07 to 0.33) | 0.15 (0.07 to 0.33) | 20 (22) | 881 (34.6) | 0.28 (0.15 to 0.52) | 0.32 (0.17 to 0.61) | |
*
Includes glassy cell carcinoma, clear cell carcinoma, and other rare types.
†
Adjusted for educational level and age.
‡
International Federation of Gynecology and Obstetrics stage: IA=microinvasive; IB=localised cancer; II or higher=advanced cancer.